First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Novo Nordisk current and future product portfolio covers
the type 2 diabetes treatment cascade¹
Overview of current and future products in Novo Nordisk's diabetes portfolio
Second generation
analogues
First generation
analogues
Human insulin
When basal insulin is not enough
When
metformin is
not enough
When it's time
for insulin
Once-daily
optimisation
Mealtime insulin control
Slide 41
oral semaglutide
OZEMPİC
TRESIBA
Xultophy
RYZODEG
Fiasp
fast-acting insulin aspart
semaglutide injection
or
VICTOZAⓇ
LevemirⓇ
Novo Mix®
Novo Rapid
or
Insulatard®
Mixtard® 30
ActrapidⓇ
1 Pending clinical development programmes and regulatory processes for oral semaglutide
changing
diabetes®
novo nordiskView entire presentation